19 March 2025 - "We believe convincing our headquarters is no longer feasible, and we have no plans to apply for reimbursement in the future."
This is what this reporter recently heard from a global pharmaceutical company official. For an expensive anti-cancer drug, giving up on reimbursement in Korea was tantamount to abandoning the Korean market.